Biotech Report: Evotec (EVT) Rises, Qiagen (QIA) Slips Amid Market Fluctuations

A look at the stock market and the performance of biotech stocks shows some companies are doing well, while others are losing value in afluctuating market. The DAX corrected by 0.6 percent to 19,909 points, weighed down by BASF, BMW and Bayer. On the other side were Hannover Re, RWE and Siemens Energy.

The MDAX lost 0.7 percent to 25,531 points. The TecDAX corrected by 0.6 percent to 3,416 points. 1&1, TeamViewer and Aixtron lost ground here. Süss MicroTec, PNE and Nordex rose.

Biotech stocks in the focus

The Hang Seng Index rose by 0.7 percent to 19,760 points, the Chinese CSI 300 Index lost 1.2 percent to 3,775 points.

The Euro Stoxx 50 lost 1.0 percent to 4,870 points, the FTSE 100 Index lost 0.4 percent to 8,228 points.

In the USA, the current ISM purchasing managers index for the manufacturing sector was published in December. The index rose by 0.9 to 49.3 points, exceeding expectations.

The Dow Jones Index currently rose by 0.6 percent to 42,645 points, the NASDAQ gained 1.5 percent to 19,565 points.

In German trading, biotech companies like Biotest lost 0.7 percent to EUR 27.00 and 4SC lost 0.7 percent to EUR 5.56. Qiagen lost 0.4 percent to EUR 43.47.

On the other hand, BB Biotech gained 2.4 percent to EUR 39.00. Evotec gained 1.7 percent to EUR 8.47. Biontech gained 0.4 percent to 112.90 euros.

On Wall Street, the NASDAQ Biotech Index rose 1.0 percent to 4,379 points

Biotech stocks experienced positive movement, with several key players recording gains. Gilead Sciences saw a modest rise of 0.2 percent to $92.05, while Amgen increased by 0.8 percent to $261.26, and Regeneron climbed 0.6 percent to $719.59.

Arrowhead Pharma led with a 2.3 percent jump to $20.10, followed by Biogen up 1.6 percent to $152.41, and Vertex Pharma advancing 1.3 percent to $410.98. This upward trend highlights renewed investor confidence in the biotech sector.

__

(Featured image by TabTrader.com via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in shareribs. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us